MA45563B1 - Méthodes de traitement du cancer de l'ovaire - Google Patents
Méthodes de traitement du cancer de l'ovaireInfo
- Publication number
- MA45563B1 MA45563B1 MA45563A MA45563A MA45563B1 MA 45563 B1 MA45563 B1 MA 45563B1 MA 45563 A MA45563 A MA 45563A MA 45563 A MA45563 A MA 45563A MA 45563 B1 MA45563 B1 MA 45563B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- treatment
- ovarian cancer
- cancer
- administering
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000012661 PARP inhibitor Substances 0.000 abstract 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des méthodes d'administration d'un inhibiteur de parp à un patient atteint d'un cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356461P | 2016-06-29 | 2016-06-29 | |
| PCT/US2017/040039 WO2018005818A1 (fr) | 2016-06-29 | 2017-06-29 | Méthodes de traitement du cancer de l'ovaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45563A MA45563A (fr) | 2019-05-08 |
| MA45563B1 true MA45563B1 (fr) | 2024-05-31 |
Family
ID=91486473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45563A MA45563B1 (fr) | 2016-06-29 | 2017-06-29 | Méthodes de traitement du cancer de l'ovaire |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA45563B1 (fr) |
-
2017
- 2017-06-29 MA MA45563A patent/MA45563B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA45563A (fr) | 2019-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018077492A2 (pt) | métodos de tratamento de câncer de ovário | |
| MA39984B1 (fr) | Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné | |
| MD3416631T2 (ro) | Agenți terapeutici pentru bolile neurodegenerative | |
| MA49760B1 (fr) | Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique | |
| CL2018002924A1 (es) | Inhibidores de bromodominios | |
| MA38495A1 (fr) | Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| EA201892740A2 (ru) | Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk) | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| CO2017001875A2 (es) | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| BR112022008294A2 (pt) | Composições de profármaco e métodos de tratamento | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| MA45780B1 (fr) | Niraparib pour son utilisation dans une méthode de traitement du cancer de la prostate | |
| EA201991580A1 (ru) | Пиримидиновое соединение и его фармацевтическое применение | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| MA40607B1 (fr) | Traitements médicaux à base d'anamoréline | |
| MA46459B1 (fr) | Méthode de traitement de lésions rénales aiguës | |
| EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
| MX388592B (es) | Compuestos y metodos terapeuticos. | |
| EA201492104A1 (ru) | Ингибитор jak1/2 | |
| EA201791819A1 (ru) | Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias |